Trial Profile
A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Ragweed SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis; Asthma; Ragweed pollen hypersensitivity
- Focus Adverse reactions
- Sponsors Circassia; Niox
- 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 25 Feb 2014 New trial record